Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2014

Parallels between cancer and infectious disease
Richard S. Hotchkiss
Washington University School of Medicine in St. Louis

Lyle L. Moldawer
University of Florida

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Hotchkiss, Richard S. and Moldawer, Lyle L., ,"Parallels between cancer and infectious disease." The New
England Journal of Medicine. 371,4. 380-383. (2014).
https://digitalcommons.wustl.edu/open_access_pubs/3141

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

The

n e w e ng l a n d j o u r na l

of

m e dic i n e

clinical implications of basic research
Elizabeth G. Phimister, Ph.D., Editor

Parallels between Cancer and Infectious Disease
Richard S. Hotchkiss, M.D., and Lyle L. Moldawer, Ph.D.
Infectious diseases and cancer have multiple
similarities. Both infectious organisms and cancer cells express many proteins that are recognizable by host T cells,1 and both elicit T-cell–
mediated inflammation. An essential aspect of
T-cell homeostasis is that the responses of these
cells must eventually diminish to avoid toxicity
from excessive T-cell proliferation and cytokine
release. Unfortunately, this can lead to a loss of
appropriate T-cell responses, especially in advanced cancer and chronic infections.
Scientists have identified many of the normal
mechanisms in cancer and indolent infections
that ordinarily limit T-cell responses. These
findings have led to the development of agents
that can overcome the limiting mechanisms to
“unleash” or amplify ongoing T-cell responses
under conditions of adaptive immune suppression.2 These agents are designed to alleviate or
reverse such events as “T-cell exhaustion”
brought about by inhibitory molecules (e.g., programmed cell death 1 [PD-1] and programmed
cell death ligand 1 [PD-L1]), an increased number of myeloid-derived suppressor and T-regulatory cells, decreased expression of HLA-DR by
antigen-presenting cells, and a shift from M1
(killer) macrophages to M2 macrophages, which
dampen the immune system by secreting antiinflammatory cytokines such as interleukin-10
(Fig. 1). Many of the agents that can expand the
T-cell response are being developed for cancer
therapy.3 Similarly, agents that block immunosuppressive proteins or cytokines that suppress
T-cell responses (e.g., antibodies that counter
interleukin-10 and transforming growth factor β)
are also being developed as potential drugs for
treating cancer. Several of these agents are also
likely to be efficacious in patients with chronic
infectious diseases.
Why do cancer and many infectious disor-
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ders induce similar immunologic responses?
Persistent immune activation and inflammation
play key roles. Chronic antigenic stimulation
caused by damage-associated molecular pattern
(DAMP) and pathogen-associated molecular pattern (PAMP) molecules occurs in cancer and infectious disorders, respectively. DAMPs and
PAMPS bind to similar or, in some cases, identical toll-like receptors (TLRs) and NOD-like receptors (NLRs), which unlike most receptors are
able to respond to a variety of conserved foreign
Figure 1 (facing page). Immune Phenotypes of Cancer
and Protracted Infection.
Tumor and pathogen antigens persistently activate
T cells, which ultimately leads to T-cell exhaustion.
Chronic release of damage-associated molecular pattern (DAMP) molecules and pathogen-associated molecular pattern (PAMP) molecules occurs in cancer and
infectious disorders, respectively, leading to activation
of common signaling pathways mediated by toll-like receptors (TLRs) and NOD-like receptors (NLRs), which
regulate immunity (see the Glossary). Protracted inflammation that is caused by reactive oxygen and nitrogen species also occurs in both disorders. Apoptotic
tumor or immune cells are engulfed by phagocytic
cells, which subsequently release immunosuppressive
cytokines. Collectively, these processes lead to an
immunosuppressive environment with “exhausted”
T cells expressing inhibitory molecules (e.g., programmed cell death 1 [PD-1] and programmed cell
death ligand 1 [PD-L1]), increased numbers of T-regulatory cells and myeloid-derived suppressor cells, and
a shift from type 1 helper T (Th1) cells to type 2 helper
T (Th2) cells and from M1 to M2 macrophages. Tumor
cells, vascular endothelial cells, myeloid-derived suppressor cells, and infected parenchymal cells express
PD-L1, which associates with the inhibitory receptor,
PD-1, to induce the suppression of T cells and natural
killer cells, thereby preventing the destruction of tumors or pathogens. Red arrows represent the secretion
of molecules with inhibitory function. PMN denotes
polymorphonuclear leukocyte, and TGF-β transforming
growth factor β.
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Glossary
Programmed cell death 1 (PD-1): Inhibits T-cell function and can trigger apoptosis; is present on T-cells.
Programmed cell death ligand 1 (PD-L1): Binds to or activates the PD-1 receptor, which is present on antigen-presenting cells and, less frequently,
on T cells.
Cytotoxic T-lymphocyte antigen 4 (CTLA4): Inhibits T-cell function and is
present on T cells.
Granulocyte–macrophage colony-stimulating factor (GM-CSF): Stimulates
the production of granulocytes and monocytes.
NOD-like receptor (NLR): Intracellular pattern-recognition receptor of PAMPs
and DAMPs.

or host ligands. Binding of TLRs and NLRs leads
to the activation of common signaling pathways
that regulate immunity. DAMPs and PAMPs
mediate and amplify inflammation, which results in the release of similar proinflammatory
and antiinflammatory cytokines, increased levels
of reactive oxygen and nitrogen species, tissue
wasting, and increased apoptosis. The totality
of these processes has detrimental effects on
host protective and antitumor immunity.
In considering new experimental approaches,
a central challenge is how to boost host immunity without causing potential adverse effects
associated with an overreactive immune system.
Serious autoimmune disorders develop in some
patients with cancer who have been treated with
immune checkpoint inhibitors of PD-1 and cytotoxic T-lymphocyte antigen 4 (CTLA4) (see the
Glossary). It is believed that such disorders result from the unleashing of ongoing or nascent
autoimmune-like T-cell responses.3 Similarly,
boosting immunity in patients with sepsis
might worsen inflammation and organ injury in
those who have not entered the immunosuppressive phase. Thus, identifying the right candidates for and timing of immunotherapy in patients with either cancer or persistent severe
infection is essential.
In two recent studies, investigators made potential advances in identifying appropriate patient populations.4,5 Using a model of chronic
viral infection in mice, Crawford et al.4 analyzed
immune effector cells at the level of the transcriptome. They identified unique gene-expression patterns involving inhibitory receptors and
transcription factors that are present in dys-
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functional CD4+ and CD8+ T cells. These findings provide a foundation for further development of a quantitative nucleic acid–based
method of identifying and targeting patient-specific immunologic defects.
Another method to gauge host immunity
uses the patient as a “test tube.” Most healthy
persons harbor numerous latent viruses (e.g.,
cytomegalovirus, herpes simplex virus type 1,
and Epstein–Barr virus), which can reactivate,
replicate, and enter the circulation during
impaired host immunity. De Vlaminck et al.

performed serial sequencing of the virome in
patients undergoing organ transplantation.5
Results showed a correlation between the total
viral load and the intensity and dose of medications used to suppress immunity and prevent
organ rejection. They also observed a correlation between the types of virus that were detected and the intensity and dose of medications. Tapering of immunosuppressive drugs led
to changes in specific viruses and a reduction in
viral loads. If replicated, tests that quantitate
the human virome may be useful in predicting
immunocompetence in hospitalized patients.
A revolution in immunotherapy is under way
in oncology, and its turbulence is beginning to
affect the experimental treatment of infectious
diseases. Granulocyte–macrophage colony-stimulating factor (GM-CSF) is in clinical trials involving patients with cancer and sepsis. Anti–
PD-1 and anti–PD-L1 drugs have been effective
in several clinical trials to treat melanoma,
non–small-cell lung cancer, and renal-cell cancer, and they are being tested in the treatment
of human immunodeficiency virus infection. Interleukin-7, one of the most promising and
broadly active immunomodulators, was efficacious in early trials involving pediatric patients
with sarcoma and was found to reverse gut pathology in patients with HIV infection or JC virus–induced progressive multifocal leukoencephalopathy.6
What next? An experimental test of these approaches to treat sepsis could be considered. On
a more general level, greater collaboration is required between oncologists, infectious-disease
specialists, translational immunologists, and
pharmaceutical companies in developing clinically relevant tests that identify patient-specific
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defects in innate or adaptive immunity. The
recently announced and unprecedented collaboration among four major pharmaceutical
companies in developing combination immunotherapeutic drugs for cancer7 underscores the
perceived importance of immunotherapy and
the recognition that teamwork is critical to success. Rapid tests of the overall health of a patient’s immune system would enable clinicians
to guide immunotherapy and follow its efficacy.
Nucleic acid–based detection of mechanisms of
immunosuppression and of reactivated latent viruses might identify candidates for immunotherapy and enable therapeutic monitoring.4,5
Coordination of clinical trials with sharing of
data and patient samples would expedite drug
development. A change in clinical outcomes —
in both cancer and infectious disease — will occur more quickly if investigators in these specialties pull together.
Disclosure forms provided by the authors are available with
the full text of this article at NEJM.org.
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